## ICMJE DISCLOSURE FORM

Date:	February 11, 2021		 _	
Your Name:	Barbara Mintzes			
<b>Manuscript Tit</b>	le:N/A		 	
Manuscript nu	mber (if known):	N/A		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	Time frame: Since the initial planning of the work					
1	All support for the present	N/A				
	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					
	No time limit for this item.					
	Time frame: past 36 months					
2	Grants or contracts from any					
	entity (if not indicated in	Australia's National Health	PI. Funds held at the University of Sydney. AUD\$1.002			
	item #1 above).	and Medical Research	million			
		Foundation: research				
		grant. 2017-2020				
		Canadian Institutes of	Co-PI. Funds held at the University of British Columbia.			
		Health Research: research	CAD \$1.16 million			
		grant funding. 2017-2021				

		University of Sydney -Yonsei University Collaboration Award 2020 - 2021 Australia-Korea Foundation AKF2020192 -Pilot study. 2021.	Co-PI. AUD\$20,000 per university; delayed due to COVID as covers travel and in-person meetings only  Co-PI. AUD \$10,000. Funds held by the University of Sydney.
		Australian Department of Foreign Affairs and Trade	
		School of Pharmacy Research Support Grant, University of Sydney, 2018	Co-PI. Funds held by the University of Sydney. \$15,000
		Michael Smith Health Research Foundation.	Research co-lead; CAD\$10,000 [funds held at University of British Columbia]
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	Health Canada 2020-2021	Expert witness in a legal case involving marketing of an unapproved product in Canada.  No payments to date – potential payment in this case during 2021.
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X_None	
12	Receipt of equipment, materials, drugs, medical	XNone	

	writing, gifts or other services		
13	Other financial or	XNone	
	non-financial interests		

Please place an "X	" next to the following	statement to indicate	your agreement:
--------------------	-------------------------	-----------------------	-----------------

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.